Zymeworks Announces Research Collaboration With Dr. Dennis J. Slamon And University of California, Los Angeles (UCLA)

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced it has entered into a collaboration with the University of California, Los Angeles through Dennis J. Slamon, M.D., Ph.D., to explore potential clinical indications in breast cancer for a number of Zymeworks’ bi-specific antibodies.

Help employers find you! Check out all the jobs and post your resume.

Back to news